NEUROGENE INC
NGNENASDAQTrading Snapshot
- Day Range
- $28.50 – $32.09
- 52-Week Range
- $15.93 – $43.66
- Volume (shares)
- 309,628
- Avg Volume (shares)
- —
- Shares Outstanding
- 20.0M
- Next Earnings
- 2026-11-23
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-3.16
- Dividend Yield
- —
- Dilution (1yr)
- +4.3%
NEUROGENE INC
NGNE
StockOtter · stockotter.spaceAbout NEUROGENE INC
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
ⓘLatest News & Updates
Neurogene Presents New Data at ESGCT Congress that Reinforce Key Differentiators of NGN-401 Gene Therapy for Rett Syndrome
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological
Intellia Therapeutics (NASDAQ:NTLA) and Neurogene (NASDAQ:NGNE) Critical Survey
Intellia Therapeutics (NASDAQ: NTLA - Get Free Report) and Neurogene (NASDAQ: NGNE - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses bas
Neurogene Announces Upcoming Presentations Highlighting Key Differentiators of NGN-401 for Rett Syndrome at the ESGCT 33rd Annual Congress
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that it
Neurogene (NASDAQ:NGNE) Sees Large Volume Increase – Should You Buy?
Shares of Neurogene Inc. (NASDAQ: NGNE - Get Free Report) saw unusually-high trading volume on Monday. Approximately 109,919 shares were traded during mid-day trading, a decline of 46% from the previous session's volume
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that th
Head-To-Head Comparison: Neurogene (NASDAQ:NGNE) & Applied Dna Sciences (NASDAQ:BNBX)
Applied Dna Sciences (NASDAQ: BNBX - Get Free Report) and Neurogene (NASDAQ: NGNE - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based o